Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Voyager Therapeutics Inc (NASDAQ:VYGR), Audentes Therapeutics (NASDAQ:BOLD) and Mallinckrodt (NYSE:MNK).
Voyager Therapeutics Inc (VYGR)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics Inc today and set a price target of $30. The company’s shares closed yesterday at $20.18.
Chattopadhyay commented:
“Our $30 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY-AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.41, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.1% and a 43.5% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Strong Buy with an average price target of $31.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
Raymond James analyst Reni Benjamin maintained a Hold rating on Audentes Therapeutics today. The company’s shares closed yesterday at $34.25.
Benjamin noted:
“We are maintaining our Market Perform rating on Audentes Therapeutics. Yesterday morning, Audentes reported 2Q18 financial results and provided an update on its gene therapy programs. Key takeaways include: 1) additional data in patients treated with AT132 for X-linked myotubular myopathy (XLMTM) demonstrated high protein expression, reductions in ventilation, and improved muscle biopsy histology; 2) dose escalation to occur in a Crigler-Najjar patient on schedule; and 3) Pompe IND to be submitted in 2019 following safety signal in primates. While we continue to applaud the company’s business model of focusing on ultra-rare diseases, in our opinion, the company’s current market capitalization adequately reflects the preclinical/clinical results seen to date and a cash position of $314 million as of 2Q18.”
According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 3.4% and a 40.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Adaptimmune Therapeutics, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Audentes Therapeutics with a $40.25 average price target, which is a 17.5% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Hold rating on the stock with a $35 price target.
.
Mallinckrodt (MNK)
Barclays analyst Douglas Tsao maintained a Sell rating on Mallinckrodt yesterday and set a price target of $20. The company’s shares closed yesterday at $29.44.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.6% and a 50.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Protagonist Therapeutics, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Mallinckrodt is a Moderate Buy with an average price target of $25.36.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
